Other languages BioXcel Therapeutics, Inc.

Equities

BTAI

US09075P1057

Market Closed - Nasdaq Other stock markets 01:30:00 15/05/2024 am IST			5-day change	1st Jan Change
2.13 ^USD	-2.52%		-9.36%	-27.80%

09/05	BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
09/05	Transcript : BioXcel Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential	22/04
Bioxcel Therapeutics, Inc. Announces Transquility In-Care Pivotal Phase 3 Trial Plan with Bxcl501 for Agitation Associated with Alzheimer's Dementia	10/04
BioXcel Therapeutics Prices $25 Million Registered Direct Offering of Shares, Warrants	25/03
50 valores para invertir en IA, salud, movilidad y energía	25/03
50 aandelen om te beleggen in KI, gezondheid, mobiliteit en energie	23/03
50 titoli per investire in AI, salute, mobilità ed energia	22/03
50 Top-Aktien für Investitionen in KI, Gesundheit, Mobilität und Energie	22/03
50 valeurs pour investir dans l'IA, la Santé, la Mobilité et l'Energie	22/03
BioXcel Therapeutics Gets European Patent for Method of Treating Agitation in Dementia	15/03
BioXcel Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	12/03
BioXcel Therapeutics Shares Soar After Terminating Proposed $60 Million Stock Offering	14/02
BioXcel Therapeutics' BXCL701 Granted FDA Fast-Track Designation to Treat Small Cell Neuroendocrine Prostrate Cancer	13/02
BioXcel Therapeutics, Inc. Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer	12/02
Top Midday Decliners	10/02
BioXcel Therapeutics Starts $60 Million Public Offering; Shares Drop	09/02
Wall Street Set to Open Modestly Higher as S&P Hovers Just Above 5,000	09/02
Positive Quarterly Earnings Boost Exchange-Traded Funds, Equity Futures Pre-Bell Friday	09/02
US Futures Nudge Higher as S&P Remains Just Above 5,000	09/02
Top Premarket Decliners	09/02

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages BioXcel Therapeutics, Inc.

Equities

BTAI

US09075P1057

Other languages

Filters